Charles Baggett, MD
Cardiovascular Disease · Rome, GANPI 1336357060
Payments from drug & device makers
Across 233 payments — averaging $23.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Pfizer$1K
- Novartis$365
- AstraZeneca$329
- E.r. Squibb & Sons, L.L.C.$263
- Atricure, Inc.$185
- plus $2K from 30 others
What the payments were for
- Speaking & faculty fees$86015%
- Travel & lodging$781%
- Food & beverage$4,57782%
- Education$381%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 84 | $1,384 |
| Pfizer | 26 | $1,340 |
| Novartis | 18 | $365 |
| AstraZeneca | 15 | $329 |
| E.r. Squibb & Sons, L.L.C. | 11 | $263 |
| Atricure, Inc. | 1 | $185 |
| Cvrx, Inc. | 2 | $156 |
| Actelion Pharmaceuticals US, Inc. | 3 | $152 |
| Osprey Medical Inc | 9 | $118 |
| Boston Scientific | 3 | $93 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $91 |
| W. L. Gore & Associates, Inc. | 5 | $85 |
| Abbott | 2 | $83 |
| Lexicon Pharmaceuticals, Inc. | 5 | $80 |
| Livanova USA, Inc. | 1 | $78 |
| Chiesi USA, Inc. | 4 | $74 |
| Esperion Therapeutics, Inc. | 4 | $73 |
| Medtronic | 4 | $71 |
| Cordis US CORP. | 3 | $68 |
| Novo Nordisk | 3 | $57 |
| Boehringer Ingelheim | 2 | $53 |
| Amgen | 3 | $46 |
| Lantheus Medical Imaging, Inc. | 2 | $45 |
| Alnylam Pharmaceuticals Inc. | 2 | $40 |
| Biotronik Inc. | 2 | $31 |
| Impulse Dynamics (USA) Inc. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Terumo Medical Corporation | 1 | $20 |
| Bardy Diagnostics, Inc. | 2 | $17 |
| Akcea Therapeutics, Inc. | 1 | $17 |
| Merck | 1 | $17 |
| Nuwellis, Inc. | 2 | $16 |
| Baxter Healthcare | 1 | $16 |
| Varian Medical Systems, Inc. | 1 | $16 |
| Vital Connect, Inc | 1 | $15 |
| GSK | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$983
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$185
- ATRICLIP LAA EXCLUSION SYSTEM$185
- Barostim Neo System$133
- XARELTO$125
- BRILINTA$124
- UPTRAVI$124
- OPSUMIT$124
- CAMZYOS$119
How this compares
$5,552 in reported general payments places this provider in the 70th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 213 | $4,811,176 |
| VyndaqelTafamidis Meglumine | 48 | $1,047,774 |
| EliquisApixaban | 584 | $602,811 |
| XareltoRivaroxaban | 140 | $134,135 |
| EntrestoSacubitril/Valsartan | 97 | $121,912 |
| Repatha SureclickEvolocumab | 53 | $55,568 |
| BrilintaTicagrelor | 62 | $38,559 |
| FarxigaDapagliflozin Propanediol | 41 | $29,755 |
| JardianceEmpagliflozin | 26 | $28,582 |
| Atorvastatin Calcium | 830 | $7,676 |
| Carvedilol | 698 | $5,680 |
| Metoprolol Succinate | 265 | $3,452 |
| Hydralazine Hcl | 249 | $3,281 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 272 | $3,171 |
| Metoprolol Tartrate | 455 | $2,863 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $1,340 | $6,461,761845 claims |
| Johnson & JohnsonXarelto | $1,384 | $134,135140 claims |
| NovartisEntresto | $365 | $121,91297 claims |
| AstraZenecaBrilinta, Farxiga | $329 | $68,315103 claims |
| Boehringer IngelheimJardiance | $53 | $28,58226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Rome
- Hector PiconRome$113K
- Charles JacksonRome$55K
- Narendra SinghJohns Creek$5.4M
- Elizabeth OfiliAtlanta$4.5M
- Sanjay YadavAtlanta$3.7M
- Arshed QuyyumiAtlanta$3.4M
- Naresh ParikhNorcross$2.8M
- Nicolas ChronosEatonton$2.4M
- Bobby KhanAtlanta$1.7M
- Hunter ChampionColumbus$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.